Class Action Lawsuits Filed Against Evolv and Edwards

A series of lawsuits have been filed against Evolv Technologies Holdings, Edwards Lifesciences Corporation, and Elanco Animal Health Incorporated for alleged violations of federal securities laws. Evolv is facing claims regarding material misstatements in its financial statements related to revenue recognition between Q2 2022 and Q2 2024, which led to the company advising investors that these statements should not be relied upon. Edwards Lifesciences is accused of misleading investors about the demand for its Transcatheter Aortic Valve Replacement (TAVR) therapies, leading to a significant drop in financial guidance. Similarly, Elanco is being sued for allegedly misrepresenting the approval status of its veterinary drugs Zenrelia and Credelio Quattro, which resulted in a sharp decline in stock price after the FDA review was delayed. Investors in all three companies have set deadlines to join the lawsuits and are encouraged to seek further information. These cases highlight ongoing concerns regarding transparency and accuracy in financial reporting within the tech and healthcare sectors.